New combo therapy shows promise for tough pancreatic cancer
NCT ID NCT03264404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, pembrolizumab (an immunotherapy) and azacitidine (a drug that affects gene activity), in people with advanced pancreatic cancer that had worsened after initial treatment. The goal was to see if this combination could help control the cancer. About 36 participants received both drugs on a regular schedule. This was an early-phase trial to check safety and effectiveness, and it was not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?